AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

Could We Have Prevented STEMI? A Real-World Comparison of PREVENT and Pooled Cohort Equation Risk Assessment for Primary Prevention

By McFall A, Almadaineh M, Rivera C et al.

Introduction/Background: Cardiovascular disease remains a leading cause of morbidity and mortality despite effective preventive therapies. Although statins reduce cardiovascular risk, many patients who ultimately experience ST-elevation myocardial infarction (STEMI) are not receiving appropriate primary prevention. The recently developed PREVENT risk equation was designed to provide a broader assessment of cardiovascular risk than the traditional Pooled Cohort Equation (PCE). This study compared PCE and PREVENT risk estimates among patients presenting with STEMI and evaluated missed opportunities for primary prevention. Research Question/Hypothesis: Among patients who ultimately experienced STEMI, would PREVENT identify more patients at elevated cardiovascular risk and eligible for primary prevention compared with PCE? It was hypothesized that PREVENT would identify a greater proportion of high-risk patients. Methods/Approach: A retrospective case series of 12 patients admitted with STEMI at a community teaching hospital was conducted. Demographics, cardiovascular risk factors, laboratory values, medication histories, and healthcare utilization data were obtained through chart review. PCE and PREVENT 10-year risk estimates were retrospectively calculated using pre-STEMI clinical data. Statin eligibility, statin use, and healthcare encounters within one year preceding STEMI were reviewed. Descriptive analyses compared risk estimates and treatment patterns. Results/Data: Mean age was 59 years. Mean PCE-estimated 10-year risk was 27.6% compared with 23.4% using PREVENT. Eleven patients (91.7%) met PCE-based statin eligibility criteria versus eight (66.7%) using PREVENT. Despite elevated cardiovascular risk, only six patients (50.0%) were receiving statin therapy before STEMI. Four patients (33.3%) had a documented missed opportunity for primary prevention. Patients averaged 3.5 healthcare encounters during the preceding year. Conclusion(s): PREVENT generated lower risk estimates and identified fewer statin-eligible patients than PCE despite all patients in this cohort subsequently experiencing STEMI. These findings suggest that PREVENT may reclassify some high-risk individuals into lower-risk categories, potentially reducing opportunities for preventive intervention. Furthermore, only 50% of eligible patients were receiving statin therapy before STEMI, underscoring persistent gaps in primary prevention. Larger studies including NSTEMI populations are needed to further evaluate PREVENT risk stratification and its impact on preventive treatment decisions.

doi.org/10.1161/circ.154.suppl_1.18938Biomarkers

AgingResearch.News